Skip to content

Study · Randomized controlled trial · n = 15 · 2020

3 results

The effect of pituitary adenylate cyclase-activating peptide-38 and vasoactive intestinal peptide in cluster headache.

Vollesen ALH, Snoer A, Chaudhry B, Petersen AS, Hagedorn A, Hoffmann J, Jensen RH, Ashina M

Cephalalgia : an international journal of headache22 Sept 2020Cited by 30 (Europe PMC)

PMID32962406 (opens in a new tab)DOI10.1177/0333102420940689 (opens in a new tab)PepBankPUB-32962406
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialOther

    In chronic cluster headache, VIP induced cluster-like attacks in 7 of 15 patients, the same number as PACAP38.

    In plain wordsIn people with chronic cluster headache, VIP triggered attacks in 7 of 15 patients, the same as PACAP38.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeCluster-like attacks in chronic cluster headache
    Study

    n = 15

    Comparator
    PACAP38 (10 pmol/kg/min)
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    8 pmol/kg/min · intravenous · 20 minAs given in this study (human).

    Source sentences

    Summary
    In chronic cluster headache, PACAP38 and vasoactive intestinal peptide both induced cluster-like attacks in 7/15 patients (p = 0.765).
    1 context sentence
    Summary · context
    In a double-blind crossover study, 14 episodic cluster headache patients in active phase, 15 episodic cluster headache patients in remission phase and 15 chronic cluster headache patients were randomly allocated to receive intravenous infusion of PACAP38 (10 pmol/kg/min) or vasoactive intestinal pep…
  2. 02HumanRandomized controlled trialOther

    In episodic cluster headache in the remission phase, neither VIP nor PACAP38 induced cluster-like attacks.

    In plain wordsIn people with episodic cluster headache in remission, neither VIP nor PACAP38 triggered attacks.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeCluster-like attacks in episodic cluster headache, remission phase
    Study

    n = 15

    Comparator
    PACAP38 (10 pmol/kg/min)
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    8 pmol/kg/min · intravenous · 20 minAs given in this study (human).

    Source sentences

    Summary
    In episodic cluster headache remission phase, neither PACAP38 nor vasoactive intestinal peptide induced cluster-like attacks.
    1 context sentence
    Summary · context
    In a double-blind crossover study, 14 episodic cluster headache patients in active phase, 15 episodic cluster headache patients in remission phase and 15 chronic cluster headache patients were randomly allocated to receive intravenous infusion of PACAP38 (10 pmol/kg/min) or vasoactive intestinal pep…
  3. 03HumanRandomized controlled trialOther

    In episodic cluster headache in the active phase, VIP induced cluster-like attacks in 5 of 14 patients, not significantly different from PACAP38 (6 of 14).

    In plain wordsIn people with active episodic cluster headache, VIP triggered attacks in 5 of 14 patients, similar to PACAP38.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeCluster-like attacks in episodic cluster headache, active phase
    Study

    n = 14

    Comparator
    PACAP38 (10 pmol/kg/min)
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    8 pmol/kg/min · intravenous · 20 minAs given in this study (human).

    Source sentences

    Summary
    In episodic cluster headache active phase, PACAP38 induced cluster-like attacks in 6/14 patients and vasoactive intestinal peptide induced cluster-like attacks in 5/14 patients (p = 1.000).
    1 context sentence
    Summary · context
    In a double-blind crossover study, 14 episodic cluster headache patients in active phase, 15 episodic cluster headache patients in remission phase and 15 chronic cluster headache patients were randomly allocated to receive intravenous infusion of PACAP38 (10 pmol/kg/min) or vasoactive intestinal pep…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:40 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.